Industry dynamics
(Fudan version) China's hospital rankings are here!
On November 25, the Hospital Management Institute of Fudan University officially released the "2022 China Hospital Comprehensive Ranking" and "2022 China Hospital Specialty Comprehensive Reputation Ranking". In terms of the ranking rate, the proportion of Beijing, Shanghai and Guangzhou hospitals in the top 30 has dropped from 2 3 in 2010 to 1 2 this year. In addition, new disciplines have been added to this year's specialty rankings, including three disciplines: pain science, sports medicine and rare diseases. This has increased the list from 18 disciplines at the beginning of its inception in 2010 to 45 today. The 2023 Hospital Internet Influence Index is released!On November 28, 2023, the well-known domestic Internet medical platform Good Doctor** released the 2023 National Hospital Internet Influence Index (hereinafter referred to as the "Index"), which is the eighth consecutive year that the Index has been released. The index is based on the real doctor-patient behavior data of the Good Doctor ** platform over the past 17 years, and the index is based on 667400 million patient views, 86.5 million patient Internet medical service records, 9300 million doctor-patient exchanges, 619A comprehensive index of online medical treatment options for patients in 36 specialties in 2023 was obtained through a study of 50,000 online and offline evaluations of patients after they were treated in hospitals.
Beijing's artificial intelligence industry model is innovatively applied to solve the pain points of medical servicesAccording to relevant reports, the size of China's large-scale model market will be about 5 billion yuan (RMB) in 2023. Companies plan to release a large number of large model budgets in 2024, so the market size will grow significantly, and is expected to reach 12 billion yuan. At present, the Beijing model has been implemented in the fields of government affairs, finance, and medical care. Focusing on the four dimensions of innovation, demonstration, economic and social benefits, and scalability, the innovative application of large models in the artificial intelligence industry in Beijing has selected typical cases in many medical fields, such as "Yunzhisheng builds an outpatient electronic medical record automatic generation system based on the Shanhai model", "Zhipu Huazhang builds a digital Chinese medicine model", and "Shukun Technology builds a cardiopulmonary intelligent health management service platform based on a digital human body model". Hu Jinglin, the first director of the National Health Insurance Administration, took office and continued to promote centralized procurement and medical insurance supervisionAccording to the General Office of the State Administration of Taxation, on the morning of November 28, the relevant responsible comrades of the Organization Department attended the meeting of leading cadres of the State Administration of Taxation and announced the decision: Comrade Hu Jinglin was appointed Secretary of the Party Committee of the State Administration of Taxation and Comrade Wang Jun was removed from the post of Secretary of the Party Committee of the State Administration of Taxation. In the five years since the establishment of the National Health Insurance Bureau, the optimization of the medical insurance catalog, the centralized procurement of drug consumables, the reform of payment methods, the fight against fraud and insurance fraud, and the reform of informatization have continued to deepen, and Hu Jinglin, as the main person in charge of the National Health Insurance Bureau, is one of the promoters of this series of major initiatives. Beijing International Big Data Exchange: Accelerate the pilot of medical and health data circulation in BeijingOn November 23, at the press conference on the construction of the 2023 global digital economy benchmark city held by the Beijing Municipal Information Office, Fan Wenzhong, chairman of Beijing Financial Holding Group, introduced that the Beijing Municipal Bureau of Economy and Information Technology and the Municipal Medical Management Center are organizing and guiding the Beijing International Big Data Exchange to carry out the pilot work of medical and health data circulation in Beijing, and accelerate the data registration, evaluation, circulation, and investment of the first batch of 6 hospitals in Beijing. Report on the development of the medical and health industry of listed companies: in the future, we will focus more on high-tech and high-medical value-added products and servicesThe China Association of Public Companies released the "Medical and Health Industry Development Report of Listed Companies 2023". The report shows that in the ten years from 2012 to 2022, China's medical and health listed companies have achieved leapfrog development in the capital market: the number of listed companies has increased from 169 to 472;The total market capitalization is increased by 103 trillion yuan increased to 719 trillion yuan, with a compound annual growth rate of 207%；Total operating income is 047 trillion yuan, an increase to 247 trillion yuan, with a compound annual growth rate of 176%；Net profit increased from 37.9 billion yuan to 211.7 billion yuan, with a compound annual growth rate of 188%。
Ali Health plans to purchase the exclusive marketing review right of Alimama medical and health care for HK$13.5 billion, and Ali's shareholding ratio will increase
On the evening of November 28, Ali Health (00241HK) announced that the company entered into a share purchase agreement with a wholly-owned subsidiary of Alibaba Holdings to 135For a total consideration of HK$1.2 billion, it obtained the exclusive marketing review right of Alimama medical and health category and the subsidiary right to provide value-added services. Upon completion of the transaction, the Target Company will become a direct wholly-owned subsidiary of Alibaba Health, and the financial results of the Target Group will be consolidated into the accounts of Alibaba Health Group. Alibaba Group's stake in Alibaba Health will increase from 5699% rose to 6383%。
The latest policy is released
The National Health Commission promulgated the "Measures for the Administration of Health Statistics", which came into force on December 1
Recently, the National Health Commission promulgated the Measures for the Administration of Health Statistics (hereinafter referred to as the "Measures"), which will come into force on December 1, 2023. The Measures are divided into seven chapters and 33 articles, which are divided into General Provisions, Institutions and Personnel, Management of Statistical Survey Projects, Management of Statistical Information Services, Security Management of Data Resources, Supervision and Legal Liability, and Supplementary Provisions.
Shenzhen issued measures for the management of health data, clarifying the rules for the sharing and opening of health data
The Shenzhen Municipal Health Commission recently issued the Measures for the Management of Health Data in Shenzhen (hereinafter referred to as the "Measures"), which applies to the health data processing activities and supervision and management carried out by the health administrative departments, medical and health institutions (hereinafter collectively referred to as the responsible units) and their staff within the jurisdiction of Shenzhen. The Measures consist of seven chapters and 49 articles, including General Provisions, General Provisions on Data Processing, Data Collection, Transmission and Storage, Data Use, Processing and Deletion, Data Sharing and Openness, Security and Regulation, and Supplementary Provisions. By clarifying the management structure at all levels and the responsibilities of all relevant units, standardize the classified processing, hierarchical authorization, and shared access of health data, and strengthen the whole-process management of health data processing generated in the process of medical services, scientific research, and public services.
**Order: Comprehensively promote the leasing of medical equipment and hospitalization!
Recently, Guangdong Province issued the "Notice on the Pilot Work Plan for Equipment Leasing in the Field of Education Science and Technology, Health and Health in our Province", and simultaneously issued the "Work Plan for the Pilot Program of Equipment Leasing in the Field of Education in our Province". This document clearly states that in order to speed up the purchase of advanced equipment, alleviate the pressure of one-time financial expenditure, improve the capacity of relevant medical services and make up for shortcomings, carry out pilot projects for leasing related medical equipment in medical institutions. And this document also clearly pointed out that in 2023, it will be piloted in the First Affiliated Hospital of Guangdong Pharmaceutical University and the Fifth Affiliated Hospital of Southern Medical University. By 2024, it will be fully extended to medical and health institutions at all levels in Guangdong Province.
Investment and financing dynamics
Shengzhi Medical completed tens of millions of yuan in Pre-A round financingBiotech is a research and development company of minimally invasive tumor technology, focusing on the original medical technology enterprise of minimally invasive cancer. Based on the original technology of robots, new energy and digitalization, the company is committed to establishing a first-class tumor innovation ecosystem of laparoscopic, endoscopic and percutaneous access, and comprehensively building an original global enterprise integrating medical industry and commerce. Recently, Shengzhi Medical has completed tens of millions of yuan in Pre-A round of financing, which was led by Haimaide Venture Capital, and the old shareholder Fengyu Capital continued to increase its weight.
Caregivers received millions of yuan in Pre-A round financingAinuer is a developer of intelligent health screening products and systems, focusing on the research and development of intelligent health screening products and systems, and is committed to providing users with health monitoring and early warning products and services. It has launched the Caregiver (Government and Enterprise Version), released the "Caregiver Health Cloud" and the "Caregiver Health Screening Device (Government and Enterprise)" and has been commercialized in the military, public security, senior care, traditional Chinese medicine clinics, communities and other industries. Recently, Caregiver has completed millions of yuan in Pre-A round of financing, and the investor in this round of financing is Huasheng Renhe Capital. The investment funds will be mainly used for product research and development and marketing.
Sleeping Cat received strategic investment from Longling CapitalKe Sleep Cat is a healthy sleep management platform provider, focusing on serving the sleep health of the whole people and providing one-stop solutions. The company takes self-developed smart sleep hardware and sleep health management APP as the core, integrates sleep health-related products, and combines AI + Web30+ The cutting-edge blockchain technology and trends of big health are applied to the blockchain health ledger of the sleep track, serving ecological partners, and formulating personalized and accurate sleep management solutions through sleep detection, monitoring, risk early warning systems and health ledgers. Allow users to get high-quality, healthy sleep. Recently, Ke Sleeping Cat received a strategic investment from Longling Capital, with a post-investment valuation of 1300 million, officially entered the capital market.
Cradle Bio received a $24 million strategic investment
Cradle Bio is a Swiss biotechnology service provider focusing on the design and improvement of proteins based on AI technology in the field of healthcare services. Recently, Cradle Bio received a $24 million strategic investment from Kindred Capital, Index Ventures and individual investors.
Gain Therapeutics received a $10.1 million strategic investment
Gain Therapeutics is a neurological disease technology developer dedicated to the discovery and development of the next generation of metabiogenesis**. The Company's SEE-TX discovery platform leverages AI-powered structural biology, proprietary algorithms, and supercomputer-powered physics-based models to identify novel heterogeneous binding sites on disease-affected proteins, pinpointing pockets that are undiscoverable with current technologies or undiscoverable by drugs. Recently, Gain Therapeutics announced that it has raised $10.1 million in funding.
Novorex received 887$510,000 Series A financingNocrex is a small molecule drug developer focused on the development of small molecule drugs using the 3D structure of proteins and molecular calculations. The Company enables seamless drug development through an advanced AI-powered drug development platform and expertise in the field of fragment drug development (FBDD). It focuses on the development of small molecule drugs for oncology and neurological diseases, with a focus on using artificial intelligence technology to identify early-stage drug candidates and verify their binding to target proteins, efficiently and accurately discover potential drug candidates, including undruggable targets, and accelerate the drug discovery process to reduce the time costs associated with traditional high-throughput screening (HTS) methods. Novorex announced that it has acquired 887$510,000 Series A financing. The round was led by existing investors Woori Venture Partners, Company K Partners, UTC Investment and BN Investment, with new investors including KB Investment, AON Investment, Quad Asset Management, Hana Ventures and Technology Assurance fund。
Prelude Products raised $5.2 million in seed round
Prelude is an ecosystem AI chain solution provider. Designed to reduce stockouts and backlogs in pharmacies to increase sales, profitability, and cash flow. Recently, Prelude Products received a seed round of financing, with investment from Casa Verde Capital and Rackhouse Venture Capital.
Bidding for medical informatization projects
Xinjiang Uygur Autonomous Region Medical Security Bureau medical insurance management grassroots cloud service project
Potential bidders for the grassroots cloud service project of the Xinjiang Uygur Autonomous Region Medical Security Bureau should obtain the bidding documents online on the Zhengcaiyun platform and submit the bidding documents before 11:00 (Beijing time) on December 21, 2023. Budget amount: 471950,000 yuan.
Municipal system operation and maintenance services of the national unified medical insurance information platform
Potential bidders for the bidding project of the municipal system operation and maintenance service of the national unified medical insurance information platform should carry out the "bidder login" in the "Handan Public Resources Trading Center", fill in the relevant information and sign the credit commitment to upload the bidding documents by themselves. **Technical service**: 0310-8031630 to obtain the bidding documents, and submit the bidding documents before 09:30 on December 27, 2023 (Beijing time). Budget amount: 9.88 million yuan.
The Second People's Hospital of Taiyuan City, Taiyuan City Regional Medical Care and Elderly Care Diagnosis and Treatment Center Information Construction Project
Potential bidders for the public bidding and procurement of the information construction project of the Taiyuan Regional Medical Care Integrated Diagnosis and Treatment Center of the Second People's Hospital of Taiyuan City shall be in the Shanxi branch of the China ** procurement network (www.).ccgp-shanxi.gov.cn), click on "Potential Contractor" below the project procurement announcement for free** bidding documents. Budget amount: 942393353 million yuan.
Jinan Municipal Medical Security Bureau, Municipal Medical Insurance Bureau, DRG paid third-party service project
Potential bidders for the bidding project of DRG paid third-party service project of the Municipal Medical Insurance Bureau should obtain the procurement documents in the corresponding announcement and submit the corresponding documents before 2023-12-11 09:00 (Beijing time). Budget amount: 2 million yuan. Changjiang Medical Group county-level two-hospital hospital medical insurance DIP refined management system projectChangjiang Medical Group's county-level two-hospital hospital medical insurance DIP refined management system project Potential suppliers of the procurement project should obtain the procurement documents in Room 2302, Unit 2, Building 5, Phase II, HNA Haoting South Garden, Guoxing Avenue, Qiongshan District, Haikou City, Hainan Province, and submit the response documents before 16:00 on December 7, 2023 (Beijing time). Budget amount: 1.6 million yuan.
Cutting-edge technology
Nature Medicine: Artificial intelligence helps improve the early screening rate of pancreatic cancer.
Recently, under the leadership of the Shanghai Institute of Pancreatic Diseases, the research team, together with Ali Damo Academy, the First Affiliated Hospital of Zhejiang University School of Medicine and other institutions, built a unique in-depth Xi framework, and finally trained it as a pancreatic cancer detection model (PANDA). According to Cao Kai, panda uses a segmentation network (U-Net) to locate the pancreas, a multi-task network (CNN) to detect lesions, and a dual-channel Transformer module to distinguish pancreatic cancer from other pancreatic lesions. To put it simply, the "three-step method" is to use AI to magnify and identify those subtle pathological features in non-scan CT images that are difficult to identify with the naked eye. The CT training set for pancreatic tumors constructed by this model has included 3208 surgical cases, which have been verified by 10 hospitals around the world and measured 929% sensitivity (accuracy in judging the presence of pancreatic tumors) and 999% specificity (accuracy in judging the absence of tumors). In a real-world retrospective trial of 20,530 people, the model identified 31 clinically missed lesions, including 2 patients with early-stage pancreatic cancer who had completed surgery**. The research results have been published in the form of original papers in the international medical journal Nature Medicine.